trial

Safety and Tolerability of BI 409306 in Patients With Schizophrenia

NCTId NCT01892384
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 40 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2013-12-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2013-06-28
Primary completion
2013-12-05
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
BI 409306

Sponsors

Boehringer IngelheimLead Sponsor

Sites

1 total
Austin, United States

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE1
Primary Completion Date
2013-12-05
Status
COMPLETED
relationships
The graph out of here
drug
BI 409306
drug
lead_sponsor
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication